Panel members with expertise in selecting and developing assays, animal models, structural models and clinical trials are assets to the successful and efficient discovery and development of therapeutics for clinical advancement.
A neuropharmacologist with more than 30 years’ experience in both the academic and industrial sectors.
Chair, Innovation Support Center, Harrington Discovery Institute
Member, Scientific Advisory Board, BioMotiv
Professor, Pharmacology, University of Pennsylvania
Former VP, Bristol-Myers Squibb
An expert in preclinical and clinical planning and strategy with more than 30 years’ combined experience in clinical pharmacology and pharmaceutical development.
Special Advisor to the President for Corporate Relations, MUSC
Former President and COO, Forest Laboratories, Inc.
Medicinal chemistry experts with decades of experience in the synthesis and alteration of organic compounds contribute to the discovery and optimization of lead compounds and series without claiming rights to any intellectual property. These industry veterans know how to help our scholars identify compounds with a high likelihood of becoming therapeutic agents.
A consultant in medicinal chemistry with more than 30 years’ experience in drug development and discovery at ICI Pharmaceuticals through its spin-off as Seneca Pharmaceuticals and subsequent merger with Astra Pharmaceuticals to form AstraZeneca Pharmaceuticals.
Former Senior Principal Scientist, CNS Chemistry, AstraZeneca Pharmaceuticals
A consultant in medicinal chemistry with more than 25 years’ experience in drug discovery and development.
Former VP, Schering-Plough
Former Senior Director, Merck
A medicinal chemist by training with a long track record of producing new molecular entities (NMEs) that advanced into human clinical trials. He has deep experience in drug discovery and additional breadth of knowledge that includes drug development and operations. His knowledge of multiple therapeutic areas includes oncology, urology, CNS, hematology, reproductive medicine, metabolic, cardiovascular and inflammation.
Former Global Head of Chemistry at Johnson & Johnson Pharmaceutical R&D
Advisory Board Member for The Institute for Chemical Biology and Drug Discovery SUNY at Stony Brook
Scientific Advisory Committee member, University of Pennsylvania, Department of Chemistry
Scientific Advisory Committee member, Rutgers University, Department of Chemistry
Has extensive expertise in small molecule drug discovery with over 30 years of experience in medicinal chemistry.
Former VP, Schering-Plough
Former Senior Scientist, Revlon Health Care
A consultant with 30 years’ experience in the biotechnology and pharmaceutical industries. Has expertise in drug discovery strategy development and execution, medicinal chemistry and the application of transformative technologies.
Former VP, Oncology and Early Discovery Chemistry, Bristol Myers Squibb
Panel members with a strong background in pharmacology advise scholars on safety, toxicology, pharmacokinetics and pharmacodynamics, providing an expert eye to evaluate experimental results and suggest strategic next steps.
A consultant in pharmacology with more than 25 years’ research and development experience in small molecule and protein therapeutics from IND to NDA/BLA.
Former VP, Development, TetraLogic Pharmaceuticals
Former Director of Pharmacokinetics, Centocor – Johnson and Johnson
Logged over 25 years in both large pharmaceutical and biotechnology drug development activities including: toxicologic assessment of drug candidates, biomarker development, and animal care and use. He has conducted of all aspects of preclinical toxicology and biomarker development from discovery to product registration with emphasis on oncology and antiviral compounds.
Formerly Principal Toxicologist with Affigility Solutions
Former Principal Research Fellow in Toxicology & Molecular Markers for OSI Pharmaceuticals
Former Director, Toxicology Safety Assessment and Animal Facility for Gilead Pharmaceuticals
With an eye to the clinic, panel members with years of experience in regulatory strategy and planning offer an important perspective in guiding early discoveries toward investigational and marketing success.
A specialist in retinal research and development with extensive experience in the identification and assessment of licensing opportunities across multiple therapeutic areas.
Former VP, Retina Translation Medicine, Allergan and Alcon
Former Ophthalmology & Clinical Head, Novartis
A consultant with extensive expertise in strategic product development in the areas of Psychiatry, Neurology, Ophthalmology and Oncology. He is well versed in the use of portfolio management tools such as MS Project as well as other commercial and open source project planning tools.
Former Program Director at Alkermes for multiple indication therapies
Former Director, Neuroscience Program Management, Wyeth
A regulatory strategy expert with over 30 years of clinical and industry experience.
Former Senior Director, The Stem Cell Organization, formerly of Johnson & Johnson
Advisors with specialty skills in key scientific and/or therapeutic areas lend a deep understanding to complex drug discovery projects.
A drug discovery professional and talented leader with more than 25 years in the pharma/biotech industry with expertise in Neuroscience. He has had success in preclinical candidate delivery and translating preclinical data sets to the clinic, as well as developing therapeutics and translational data sets for Duchenne’s muscular dystrophy.
Former Vice President of Research, EnVivo Pharmaceuticals
Former Director, Neuroscience/Genetically Defined Diseases Biology and Head, Clinical Biomarkers GDD, Bristol-Myers Squibb
Former Executive Director, CNS Discovery Operations, Pfizer
A consultant with more than 40 years’ experience in the academic, government, and industrial sectors applying innovative chemical and protein technology to drug discovery.
Former VP of Chemical and Protein Technologies, Bristol-Myers Squibb
Former Senior Director of Physical Sciences, DuPont Pharmaceutical Company
A consultant with extensive experience in nucleic acids (NA) research and drug discovery. She has deep expertise with in vitro screening and identification of potent molecules for in vivo studies, as well as for cellular and molecular experiments.
Formerly Head of Nucleic Acid Research Group at Bristol-Myers Squibb; Collaborated with Ionis Pharmaceuticals in discovery of nucleic acid PCSK9 clinical candidate
Over 30 years of experience in pharmaceutical development with an emphasis on formulation, CMC, and chemistry related IND components.
Former VP, Biopharmaceutics Research & Development, Bristol-Myers Squibb
An industry and start-up consultant with broad experience in the utilization of structure-based drug design and biophysical approaches for the discovery of both small molecule drugs and protein biologics.
Former Senior Director, Structural Chemistry, Schering-Plough Research Institute
Harrington InnovationSupport Center